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Abstract: Detection of micrometastases plays an important role in early-stage and recurrent 
cancer diagnosis. In the study, a new method of screening micrometastases of lung cancer 
in peripheral blood by magnetic nanoparticles (MNPs) and quantum dots (QDs) was 
developed to achieve early diagnosis and recurrence prevention. MNPs were prepared by 
combining miniemulsion polymerization and Stöber coating methods. QDs were prepared 
by using Cd(Ac)2 ⋅ 2H2O and oxygen-free NaHTe with thioglycolic acid as the stabilizer. 
The carbodiimide-mediated condensation method was used to couple pan-cytokeratin (pan-ck) 
antibody (Ab) to the surface of the MNPs, and Lunx and SP-A Abs to the surface of the QDs. 
After four kinds of epithelial tumor cells were enriched by MNPs coupled with pan-ck Ab 
(MNP-pan-ck), lung cancer cells A549 and SPC-A-1 were successfully identified by QDs 
with double-labeled Abs. Finally, 32 patients with non-small cell lung cancer (NSCLC) were 
collected, out of 26 cases with the enriched circulating tumor cells (CTCs), 21 cases were 
successfully identified by QDs. Therefore, a new method was established in which MNP-pan-ck 
collected CTCs and QDs with double-labeled Abs could be used simultaneously to identify 
CTCs from NSCLC patients.
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Introduction
Lung cancer is the leading cause of cancer deaths worldwide. International standards 
divide lung cancer into two types: small cell lung cancer and non-small cell lung 
cancer (NSCLC). NSCLC accounts for approximately 85% of all cases of lung 
cancer.   Surgery is the preferred treatment method for NSCLC patients. However, 
many patients remain at risk of recurrence and metastasis following surgery, and it 
is difficult for routine histopathology and imageology methods to detect metastasis. 
Therefore, more sensitive and specific methods are needed to detect lung cancer earlier 
and identify patients at highest risk for recurrence. In 2002, Bernards and Weinberg1 
presented a new model of metastasis where metastatic capacity is gained early during 
primary tumor development. Micrometastases were originally defined by pathologists 
as small occult metastases (0.2 cm in their greatest dimension). Currently, single 
circulating tumor cells (CTCs) are also called micrometastases. Indeed, single CTCs 
in cancer patients can be detected at early stages of tumor progression in peripheral 
blood. In order to detect single CTCs in peripheral blood, several different methods 
have been developed including reverse-transcription polymerase chain reaction, flow 
cytometry, and the immunomagnetic beads technique.2–7
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To date, nanomaterials and nanotechnology have shown 
great potential in disease diagnosis and therapy. Magnetic 
nanoparticles (MNPs) are a new type of nanomaterial.8 
The application of MNPs in the fields of biomedicine such 
as magnetic separation, drug delivery, magnetic resonance 
imaging, cell and tissue targeting, and transfection have 
drawn considerable attention due to their particularly large 
surface-to-volume ratio and intrinsic magnetic properties.9,10 
Quantum dots (QDs) are nanocrystals of inorganic semicon-
ductors that are restricted in three dimensions to a somewhat 
spherical shape, typically with a diameter of 2–8 nm.11 
QDs are a relatively new class of fluorescent nanomateri-
als with excellent photophysical properties which include 
  quantum-size effect, high brightness, long-term photosta-
bility, high quantum yields, and more importantly, broad 
absorption spectra coupled to narrow size-tunable photolumi-
nescent emission spectra.12 These properties and advantages 
of MNPs and QDs have provided a new functional platform 
for disease diagnosis and therapy.
It is well known that NSCLC is a type of epithelial 
cancer. Pan-cytokeratin (pan-ck) are currently the usual 
protein markers for the detection of epithelial tumor cells.13 
Lunx, a novel human lung-specific gene, has been reported 
to be a superior diagnostic marker for the detection of 
micrometastases in peripheral blood and lymph nodes of 
NSCLC patients.14 Surfactant protein-A (SP-A) is the most 
prominent of the four proteins in the pulmonary surfactant 
system. Moreover, expression of SP-A was also described 
for a portion of NSCLC facilitating a diagnostic marker for 
these carcinomas.15,16
Since CTCs have very low concentration in the 
blood (1 per 106–7 leukocytes), a primary enrichment step 
must usually be performed to augment the sensitivity of 
the assay.17 This will be followed by a detection method 
that will identify CTCs. In the present study, new modified 
MNPs coupled with pan-ck Ab (MNP-pan-ck) are prepared 
to enrich peripheral blood CTCs in NSCLC patients. After 
the CTCs are isolated with the MNPs, QDs conjugated with 
Lunx and SP-A Ab are used to identify the CTCs.
Materials and methods
Preparation and modification of MNPs
Iron oxide (Fe3O4) MNPs were prepared by coprecipitation 
of FeCl2/FeCl3 (ratio 1:2) by the Massart method.18 Oleic 
acid (OA)-modified MNPs were produced by redispersing 
Fe3O4 MNP precipitate in 150 mL of water and adding an 
excess amount of OA.19 The dark suspension was stirred for 
1 hour at 70°C under the protection of N2. The oily black 
  precipitate was collected, washed three times with water, and 
then dried in an oven under the protection of N2. Miniemulsion 
polymerization was used to prepare Fe3O4/polystyrene MNPs 
according to the following procedure:20 Fe3O4 MNPs were 
modified by 0.11 g of OA and were dispersed in a solution 
of 1 mL of styrene and 0.1 g of cyclohexane with the aid of 
ultrasound to form the oil phase. 80 mg of sodium dodecyl 
sulfate (SDS) and 8 mg sodium bicarbonate were dissolved in 
30 mL of water to form the water phase. A mixture of the oil 
phase and the water phase was ultrasonicated in an ice-cooled 
bath for 10 minutes to form a miniemulsion and was transferred 
to a 250 mL four-necked flask equipped with a condenser, 
a nitrogen inlet, and a stirrer. 15 mg of potassium persulfate 
dissolved in 0.5 mL of water was added to initiate the polymer-
ization at 70°C with continual stirring at 300 rpm (magnetic stir 
bars, 25 mm × 9 mm). After 12 hours, the Fe3O4/polystyrene 
MNPs were obtained. Fe3O4/polystyrene MNPs were centri-
fuged for 120 minutes at 21,000 rpm and dried in a desiccator 
for further characterization. Fe3O4/polystyrene MNPs were 
prepared by Stöber coating methods. Carboxyl-functionalized 
Fe3O4/polystyrene MNPs were prepared by copolymerization 
of acrylic acid and styrene. Transmission electron microscope 
(TEM) images were recorded using an H-8100 microscope 
(Hitachi, Tokyo, Japan).
Preparation and modification  
of aqueous soluble CdTe QDs
Cadmium telluride (CdTe) QDs were synthesized accord-
ing to the method reported by Zhao.21 Briefly, 0.5 mmol 
Cd(Ac)2 ⋅ 2H2O (Beijing Chemical Int., Beijing, China) was 
dissolved in 100 mL of high-purity water, then 87 µL of 
thioglycolic acid (Acros, Geel, Belgium) was added into the 
mixture under stirring. 1 M NaOH was used to adjust the pH 
of the solution to 9.5. After the mixture had been degassed 
by high-purity N2 bubbling for 30 minutes, a 0.25 mmol 
oxygen-free NaHTe (Beijing Chemical Int.) solution pre-
pared by reducing Te powder by NaBH4 was injected. The 
resulting mixture was subjected to reflux until the appreci-
ated size was reached by monitoring the ultraviolet–visible 
curves of the aliquot. Fluorescence spectra of CdTe QDs were 
measured on a FS900 fluorescence spectrometer (Edinburgh 
Analytical Instruments, Edinburgh, UK). High-resolution 
transmission electron microscope (HRTEM) characteriza-
tions were performed by using a JSM-3010 (JEOL, Tokyo, 
Japan) electron microscope. In the experiment, two kinds of 
CdTe QDs were synthesized, and were named QD552 and 
QD625, respectively, based on the maximum fluorescence 
emission of the QDs.
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Coupling pan-ck Ab to the surface  
of MNPs
The carbodiimide-mediated condensation method was used 
to couple pan-ck Ab to the surface of MNPs. Briefly, 100 µL 
of MNPs were transferred to a reaction tube and coupling 
buffer (10 mM K2HPO4, 150 mM NaCl, pH 5.5) was added 
to a final volume of 1 mL. The reaction tube was shaken 
vigorously for 1 minute and then the MNPs were separated 
magnetically by placing the reaction tube in the magnetic sep-
arator (Dynal AS, Oslo, Norway) at 4°C for 5 minutes. The 
supernatant was removed, leaving the MNPs as a wet cake 
on the container wall. The MNPs were suspended in 1 mL of 
coupling buffer. 0.25 mg 1-ethyl-3-(3-  dimethylaminopropyl)
carbodiimide (EDAC) reagent (Sigma-Aldrich, St Louis, 
MO) was added to the system and stirred briefly. 50 µg 
pan-ck Ab was added to the reaction system and vortexed 
for 1 hour. The MNP-pan-ck was magnetically separated and 
the supernatant was removed. 1 mL of wash buffer (10 mM 
Tris, 150 mM NaCl, 0.1% BSA, 0.1% NaN3, 1 mM EDTA, 
pH 7.4) was added and shaken vigorously. The wash step 
was repeated three times. Finally, the MNP-pan-ck was 
resuspended in the wash buffer.
Coupling Abs to the surface  
of CdTe QDs
The resultant CdTe QDs were conjugated to different lung 
tissue-specific Abs. QD552 was conjugated to rabbit anti-
human Lunx Ab (QD552-Lunx) and QD625 was conjugated 
to rabbit anti-human SP-A Ab (QD625-SP-A) (Santa Cruz 
Biotechnology, Santa Cruz, CA). Briefly, 100 µL of 1 mM 
CdTe QD solution was mixed with 400 µL of 0.05 M borate 
buffer (pH 7.5). Then, 10 µL of 25 mg/mL EDAC freshly 
dissolved in water was added to a mixture. After incuba-
tion for 5 minutes, 20 µg Ab was added to the mixture. The 
sample was dialyzed against phosphate-buffered saline (PBS; 
10 mM, pH 7.4) after incubation in the dark for 2 hours at 
room temperature. When the dialysis was over, the QDs 
conjugated to Abs were collected.
Enriching of epithelial cancer  
cells by MNPs
Lung cancer A549, SPC-A-1, liver cancer HepG2, and colon 
cancer HCT-8 cell lines were obtained from American Type 
Culture Collection (Manassas, VA). All cells were maintained 
in Dulbecco’s modified Eagle’s medium (Gibco, Grand 
Island, NY) supplemented with 10% fetal bovine serum and 
were grown in 5% CO2, at 37°C. Diverse proportion cancer 
cells were mixed with peripheral blood mononuclear cells 
(PBMC) to achieve cell suspension (the ratios of cancer cells 
to PBMC of 1:104, 1:5 × 104, 1:105, 1:5 × 105, 1:106, 1:5 × 106, 
and 1:107). MNPs-pan-ck were added to the cell suspension 
and mixed gently for 15 minutes. Cancer cells originating 
from epithelial tumors were magnetically separated and the 
isolated cells were resuspended using PBS buffer, and then 
the separated cells were smeared onto a slide. The slides 
were stained with hematoxylin and eosin (H&E) to identify 
cancer cells.
Identification of lung cancer cells  
by immunocytochemistry
A549, SPC-A-1, HepG2, and HCT-8 cells were fixed with a 
mixture of glacial acetic acid:ethanol (volume ratio of 1:9) for 
15 minutes and air-dried for 30 minutes. Fixed cancer cells 
were penetrated with 0.3% Triton X-100 for 10 minutes. The 
cells were respectively blocked with H2O2 reagent and normal 
goat serum for 10 minutes followed by incubating the slides 
with 1 µg/mL rabbit anti-human Lunx or SP-A Ab at 4°C 
overnight. 1.5 µg/mL biotinylated goat anti-rabbit IgG was 
incubated for 30 minutes, and then streptavidin-conjugated 
horseradish peroxidase was incubated for 30 minutes.   Staining 
was achieved by adding 100 µL of 3,3′diaminobenzidine for 
5 minutes. Finally, slides were washed three times with PBS 
buffer, the nuclei were counterstained with H&E, and then 
slides were rinsed with water and dehydrated in 70%, 90%, 
and 100% ethanol, air-dried, and mounted with gum and 
viewed under an ordinary optical microscope.
Identifying lung cancer cells with  
double-labeled Lunx and sP-A Abs QDs
After using MNP-pan-ck to enrich the epithelial cancer cells, 
all cells were identified by using QD552-Lunx and QD625-
SP-A Abs QDs. Briefly, enriched cells were incubated with 
QD552-Lunx and QD625-SP-A Abs at 4°C overnight. Slides 
were washed three times with PBS buffer, mounted with 
glycerin reagent, and viewed under fluorescent microscope 
(Olympus, Tokyo, Japan).
Clinical specimens
Thirty-two patients with primary NSCLC were enrolled 
between May 2011 and October 2011 at China-Japan Union 
Hospital, including 16 males and 16 females aged between 
45–77 years old. Thirty-two patients were confirmed to have 
NSCLC after surgical inspection and were diagnosed without 
history of other epithelial tumors. NSCLC patients were 
staged using the tumor–node–metastasis system, including 
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seven cases of stage I and 25 cases of stage II–IV . Moreover, 
16 patients with benign lung diseases (BLD) and 16 healthy 
volunteers were enrolled as controls. 10 mL of blood was 
collected from all participants and PBMC were isolated by 
density gradient centrifugation. CTCs were enriched from 
PBMC by MNP-pan-ck and identified by QDs with double-
labeled Abs. The study was approved by the Institutional 
Review Board of the University Hospital. All samples were 
collected after obtaining written informed consent.
statistical analysis
All the data were analyzed with SPSS software (v 12.0; SPSS 
Inc, Chicago, IL). Experiments were performed in triplicate. 
Results were expressed as mean ± standard error of mean. 
Statistical significance was set as P , 0.05.
Results and discussion
Characterization of MNPs
Many approaches have been employed to prepare MNPs 
including conventional emulsion polymerization,22 soap-
less emulsion polymerization,23,24 inverse emulsion 
polymerization,25 miniemulsion polymerization,26 and atom 
transfer radical polymerization.27,28 Among them, miniemul-
sion polymerization has been considered as one of the most 
advantageous encapsulation methods. In the present study, 
the MNPs with defined structure and controllable magnetite 
content were successfully prepared from monolayer OA-
modified Fe3O4 nanoparticles through miniemulsion poly-
merization. Figure 1 illustrates the TEM images of different 
synthetic phases of the MNPs. Figure 1A shows the Fe3O4 
nanoparticles. The diameter of the Fe3O4 nanoparticles is in 
the range from 6 to 15 nm with an average size of 9.6 nm. 
Despite the OA-modified Fe3O4 nanoparticles, the mean 
diameter of the Fe3O4 nanoparticles is also 9 nm (Figure 1B), 
which implies that OA modification does not change the 
diameter of the Fe3O4 nanoparticles. Figure 1C shows the 
Fe3O4/polystyrene MNPs. The results demonstrate that there 
are no pure polystyrene particles and bare magnetite particles 
without polystyrene coating. Figure 1D shows the carboxyl-
functionalized Fe3O4/polystyrene MNPs. A polyacrylic acid 
layer surfaces the Fe3O4/polystyrene MNPs, which gives a 
fine hydrophily and biocompatibility to the MNPs.
Characterization of CdTe QDs
Several methods have been developed to synthesize water-
soluble QDs for use in biologically relevant studies.29,30 In 
the present experiment, two kinds of CdTe QDs were syn-
thesized (Figure 2). In Figure 2A, two kinds of QDs emit 
different colors under UV radiation: one emits green light 
and the other emits red light. The HRTEM study illustrates 
that the diameter of CdTe QDs ranges from 2.8 nm to 7.3 nm 
with an average size of 4 nm, which suggests that the CdTe 
QDs exhibit a good dispersion of particles, and no obvious 
QD aggregation can be found (Figure 2B). The fluorescence 
emission spectra of the CdTe QDs are shown in Figure 2C. 
The maximum fluorescence emission of two kinds of QDs 
are respectively 552 nm and 625 nm, which were named after 
QD552 and QD625 in this study. The average full width at 
half the maximum of the photoluminescence spectra is about 
50 nm, which shows that the monodispersity of the QDs is 
quite good. The two kinds of QDs have a broader absorp-
tion spectra which show that a single light source can be 
used to excite two-color QDs simultaneously without signal 
overlap (Figure 2D). Therefore, due to these properties, the 
synthesized QDs provided a powerful foundation for further 
applications.
MNP-pan-ck enriched epithelial  
tumor cells
Because pan-ck Ab usually can be used to increase the 
sensitivity of epithelial tumor cells detection, the study 
chose MNP-pan-ck to enrich the CTCs in NSCLC patients. 
In the experiment, it was first verified whether four kinds 
of epithelial tumor cell lines expressed pan-ck protein by 
AB
D C
50 nm 50 nm
100 nm 200 nm
Figure  1  TEM  images  of  different  synthetic  phases  of  the  MNPs.  (A)  Fe3O4 
nanoparticles. (B) OA-modified Fe3O4 nanoparticles. (C) Fe3O4/polystyrene MNPs. 
(D) Carboxyl-functionalized Fe3O4/polystyrene MNPs.
Abbreviations: OA, oleic acid; MNPs, magnetic nanoparticles; TEM, transmission 
electron microscopy.
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using the immunocytochemistry (ICC) method. The results 
show that the four kinds of epithelial tumor cells express 
pan-ck protein (Figure 3), which proves that pan-ck might 
be a protein probe for the enrichment of epithelial tumor 
cells. Secondly, in order to mimic an in vivo environment, 
the four kinds of epithelial tumor cell lines were mixed with 
PBMC in different proportions in vitro. Then, MNP-pan-ck 
was used to enrich the four kinds of epithelial tumor cells. 
With a ratio of cancer cells to PBMC of 1:5 × 106, the tumor 
cells were successfully enriched. Furthermore, the enriching 
of cancer cells was increased by elevating the proportion 
of cancer cells to PBMC (Figure 4). After enrichment, the 
H&E-stained cancer cells demonstrate that the four kinds 
of epithelial tumor cells are successfully separated from the 
mixture of cancer cells and PBMC. However, no cells from 
PBMC were enriched (Figure 5).
Collectively, in order to mimic an in vivo environment, 
different kinds of epithelial tumor cells were isolated from 
the mixture of PBMC and cancer cells by using MNP-pan-ck 
in vitro. Therefore, it was thought that MNP-pan-ck might 
separate CTCs in the peripheral blood of NSCLC patients.
Expression of Lunx and sP-A in different 
cancer cells by ICC and QD methods
Because A549 and SPC-A-1 cells are derived from NSCLC, 
and Lunx and SP-A protein belong to lung tissue-specific 
proteins, it is hypothesized that A549 and SPC-A-1 lung 
cancer cells might also express Lunx and SP-A proteins, 
while liver cancer HepG2 and colon cancer HCT-8 cells do 
not express both proteins. To verify expression of Lunx and 
SP-A protein in the four kinds of cancer cells, QDs conju-
gated with Lunx and SP-A Ab were combined with the ICC 
method for detection purposes.
In our study, the traditional ICC method was used first to 
detect the expression of Lunx and SP-A protein in different 
cancer cells. We found that both A549 and SPC-A-1 cells 
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Figure 2 Properties of CdTe QDs. (A) Images of two kinds of CdTe QDs solution under ultraviolet light. (B) HRTEM images of CdTe QDs. (C) Photoluminescence spectra 
of two kinds of QDs. (D) Absorption spectrum of two kinds of CdTe QDs.
Abbreviations: HRTEM, high-resolution transmission electron microscope; QDs, quantum dots; CdTe, cadmium telluride; au, arbitrary units.
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AB CD
A549 SPC-A-1H epG2H CT-8
Figure 3 The images of pan-ck protein expression in four kinds of epithelial tumor cells by the ICC method. (A) Lung cancer A549 cells. (B) Lung cancer sPC-A-1 cells. 
(C) Liver cancer HepG2 cells. (D) Colon cancer HCT-8 cells.
Note: The magnification was 100×.
Abbreviations: ICC, immunocytochemistry; pan-ck, pan-cytokeratin.
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Figure 4 The mean number of enriching cancer cells from the different ratios of cancer cells to PBMC by MNP-pan-ck.
Notes: When the ratio of cancer cells to PBMC is 1:5 × 106 (Group 3), the cancer cells are successfully enriched by MNP-pan-ck, and when the ratios of cancer cells to 
PBMC increases, the ability to enrich cancer cells is increased. The ratios of cancer cells to PBMC: Group 1, only PBMC; Group 2, 1:107; Group 3, 1:5 × 106; Group 4, 1:106; 
Group 5, 1:5 × 105; Group 6, 1:105; Group 7, 1:5 × 104; Group 8, 1:104.
Abbreviations: PBMC, peripheral blood mononuclear cells; MNP-pan-ck, MNPs coupled with pan-cytokeratin antibody.
express Lunx protein (Figure 6A and B) and positive cell 
rates are 57.43% ± 2.47% and 48.26% ± 3.42%, respectively, 
while HepG2 and HCT-8 cells do not express Lunx protein 
(Figure 6C and D). At the same time, the results also show 
that only A549 cells express SP-A protein (Figure 6E) and 
its positive cell rate was 36.25% ± 2.66%, while SPC-A-1, 
HepG2, and HCT-8 cancer cell lines do not express SP-A 
protein (Figure 6F–H). Therefore, the results prove that Lunx 
and SP-A protein might be lung tissue-specific proteins and 
important markers of lung cancer cells.
Next, in order to assess whether QDs conjuncted with Abs 
showed similar results with the ICC method, QDs with single-
labeled Ab were used to detect the expression of Lunx and 
SP-A protein in four kinds of cancer cells. After four kinds of 
cancer cells were single-labeled with QD552-Lunx or QD625-
SP-A, both A549 and SPC-A-1 lung cancer cells emit green 
fluorescence, which indicates that two kinds of lung cancer 
cells express Lunx protein (Figure 7A and B), and positive cell 
rates were 58.37% ± 2.54% and 50.33% ± 2.97%, respectively. 
On the other hand, A549 cells only emit red fluorescence 
(Figure 7E), which indicates that only A549 cells express 
SP-A protein and its positive cell rate is 38.28% ± 3.13%. 
Furthermore, neither HepG2 nor HCT-8 cells emit any fluo-
rescence signal, which implies that these cells do not express 
Lunx and SP-A protein. There is no significant difference in 
the results between the ICC method and the method of QDs 
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with single-labeled Ab (P . 0.05). Therefore, the results 
of QDs with single-labeled Ab are consistent with the ICC 
method, which prove that QDs with labeled Ab can be used 
to detect different tumor cells.
QDs show many excellent photophysical properties. One 
of the most important is that they have broad absorption 
spectra and narrow size-tunable photoluminescent emission 
spectra. Thus, it is hypothesized that QDs with different Abs 
can be used to simultaneously check different specific mark-
ers of tumors. In order to validate this hypothesis, a combina-
tion of QD552-Lunx and QD625-SP-A was used to check 
the above four cancer cells in vitro. As shown in Figure 7I, 
A549 cells emit not only red fluorescence, but also green 
fluorescence, and the positive cell rates are 75.78% ± 3.21%, 
while the results of SPC-A-1, HepG2, and HCT-8 cells are 
the same as that of QDs with single-labeled Ab. Therefore, 
the study demonstrates that QDs with double-labeled Abs 
have more sensitivity than QDs with single-labeled Ab while 
using the ICC method.
Finally, in order to mimic an in vivo environment, QDs 
with double-labeled Abs were used to identify four kinds 
of cancer cells that had been separated from the mixture of 
c  ancer cells and PBMC by MNP-pan-ck. Figure 8 illustrates 
that A549 and SPC-A-1 cells are successfully identified by 
AB CD E
A549 SPC-A-1 HepG2 HCT-8 PBMC
Figure 5 H&E-stained cancer cells enriched by MNPs. (A) A549 cells. (B) sPC-A-1 cells. (C) HepG2 cells. (D) HCT-8 cells. (E) No cells are enriched in the PBMC group.
Note: The magnification was 100×.
Abbreviations: H&E, hematoxylin and eosin; MNPs, magnetic nanoparticles; MNP-pan-ck, MNPs coupled with pan-cytokeratin antibody.
ABCD
EFGH
A549 SPC-A-1 HepG2 HCT-8
Lunx
SP-A
Figure 6 Imaging Lunx and sP-A protein expression in different cancer cells with the ICC method. Following ICC with anti-human Lunx or sP-A Ab, the results were 
observed in the cytoplasm of different kinds of cancer cells. The brown-colored deposits (arrows) located in the cytoplasm of cancer cells indicates that the cancer cells 
express the protein. The magnification was 100×. Lunx protein can be expressed in A549 (A) and sPC-A-1 lung cancer cells (B). Lunx protein can not be expressed in HepG2 
(C) and HCT-8 cancer cells (D). sP-A protein can be expressed only in A549 lung cancer cells (E). sP-A protein can not be expressed in sPC-A-1 lung cancer cells (F),   
HepG2 (G) and HCT-8 cells (H).
Abbreviations: ICC, immunocytochemistry; sP-A, surfactant protein-A; Ab, antibody.
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using QDs with double-labeled Abs (Figure 8A and B). 
Because both HepG2 cells and HCT-8 cells did not express 
Lunx and SP-A proteins, no fluorescence signal was observed 
(Figure 8C and D).
Collectively, the expressions of Lunx and SP-A proteins 
were first verified by using the ICC method and QDs with 
single-labeled Ab. The study shows that the results of the 
two methods are very similar; A549 cells express both Lunx 
and SP-A proteins and SPC-A-1 cells only express the Lunx 
protein, while HepG2 and HCT-8 cells do not express either of 
them. Then, QDs with double-labeled Abs were used to check 
four kinds of cancer cells. It was found that this method could 
greatly improve the sensitivity of detection. Finally, QDs 
with double-labeled Abs identified lung cancer cells isolated 
by MNP-pan-ck. Therefore, this experiment found a new 
method for MNPs separation and QDs with double-labeled 
ABCD
EF GH
IJKL
A549 SPC-A-1H epG2 HCT-8
QD552-Lunx
QD625-SP-A
QDs with double-
labeled Abs
Figure 7 QDs with labeled Abs show Lunx and sP-A protein expression in different cancer cells. A549 cells (A) and sPC-A-1 cells (B) labeled with QD552-Lunx show green 
fluorescence. A549 cells (E) labeled with QD625-SP-A show red fluorescence and SPC-A-1 cells (F) labeled with QD625-SP-A do not show red fluorescence. A549 cells 
labeled with both QD552-Lunx and QD625-SP-A show both green and red fluorescence (I). sPC-A-1 cells labeled with both QD552-Lunx and QD625-sP-A show green 
fluorescence (J). Neither HepG2 nor HCT-8 cells emit any fluorescence signal (C, D, G, H, K and L).
Note: The magnification was 100×.
Abbreviations: Abs, antibodies; sP-A, surfactant protein-A; QDs, quantum dots.
AB CD
A549 SPC-A-1 HepG2 HCT-8
Figure 8 QDs with double-labeled Abs were used to identify the four kinds of enriched cancer cells. (A) A549 cells show green and red fluorescence. (B) sPC-A-1 cells show 
green fluorescence. HepG2 cells (C) and HCT-8 cells (D) do not express Lunx and SP-A proteins, no fluorescence signal was observed.
Note: The magnification was 200×.
Abbreviations: Abs, antibodies; MNP-pan-ck, MNPs coupled with pan-cytokeratin antibody; PBMC, peripheral blood mononuclear cell; QDs, quantum dots.
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Abs identified lung cancer cells from a mixture of cancer 
cells and PBMC in vitro.
Detection of CTCs from NsCLC 
patients by MNPs and QDs
After establishment of the method for enriching and 
identification of lung cancer cells in vitro, the authors 
wanted to verify if the in vitro method could be used to 
isolate and identify CTCs in peripheral blood of NSCLC 
patients. Therefore, the blood from 32 patients with 
primary NSCLC, 16 patients with BLD, and 16 healthy 
volunteers was collected. CTCs of 26 cases in 32 NSCLC 
patients were collected by MNP-pan-ck (Table 1). Of 26 
cases with the enriched CTCs, 21 cases were successfully 
identified by QDs with double-labeled Abs, including two 
cases out of seven Stage I and 19 cases out of 23 Stage 
II–IV NSCLC patients. The positive rate of identification 
was 80.77%, which showed that the method had a high 
sensitivity of isolation and identification of CTCs. No 
CTCs were obtained from the blood of 16 healthy volun-
teers and BLD using MNP-pan-ck, indicating a specific-
ity of 100%. The results suggest that a new method had 
been successfully found: MNP-pan-ck collects CTCs in 
NSCLC patients and QDs with double-labeled Abs can be 
used simultaneously to identify CTCs in NSCLC patients. 
Therefore, the method might contribute to the discovery of 
early micrometastases, prognosis evaluation, monitoring 
of recurrence, and preparation of individual postopera-
tive treatments about NSCLC patients. However, further 
clinical trials may be warranted to assess the practicality 
of the method.
Based on the above studies, Figure 9 schematically 
illustrates the processes by which the MNP-pan-ck 
enrich the CTCs from NSCLC patients and QDs with 
double-labeled Abs are used simultaneously to identify 
CTCs. Firstly, peripheral blood of different clinical 
specimens was taken, and then PBMC and CTCs were 
successfully separated by density gradient centrifugation. 
After MNP-pan-ck was used to enrich the CTCs from 
the specimens, QDs with double-labeled Abs were used 
simultaneously to identify the CTCs.
Conclusion
In this study, the synthesized MNPs were effectively coupled 
with pan-ck Ab, and two kinds of synthesized QDs were con-
jugated with Lunx and SP-A Abs. QDs with double-labeled 
Abs were first used simultaneously to identify the CTCs 
of NSCLC patients collected by MNP-pan-ck. Therefore, 
a new method of screening micrometastases of lung cancer 
in peripheral blood by MNPs and QDs was successfully 
developed.
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Table 1 The isolated and identified results of different groups
Group N MNPs enrichment (%) QDs identification (%)
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Abbreviations: MNPs, magnetic nanoparticles; QDs, quantum dots; NsCLC, non-
small cell lung cancer; BLD, benign lung diseases.
Note: In NsCLC, stage I means that the cancer is only in the lung, with normal tissue 
around it. stage II means that the cancer has spread to nearby lymph nodes. stage III 
means that the cancer has spread to the chest wall or diaphragm near the lung; to the 
lymph nodes in the area separating the two lungs (the mediastinum); or to the lymph 
nodes on the other side of the chest or in the neck. stage IV means that the cancer 
has spread to other parts of the body. Collectively, stages II–IV mean that the cancer 
has metastasized.
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Figure 9 Schematic illustration of the isolation and identification of CTCs with 
MNP-pan-ck and QDs with double-labeled antibody.
Abbreviations: Abs, antibodies; CTCs, circulating tumor cells; MNP-pan-ck, MNPs 
coupled with pan-cytokeratin antibody; PBMC, peripheral blood mononuclear cell; 
QDs, quantum dots.
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